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Inhibitor development is a lifelong challenge for patients with bleeding 
disorders who received replacement therapy. Most commonly, inhibitor 
formation was observed in hemophilia a patient, but patients with rare 
bleeding disorders (RBD) especially patients with deficiency of factor XIII 
(FXIII) and factor V (FV) can develop an inhibitor against exogenous factors. 
Several factors considered as risk factors for inhibitor formations in these 
patients. Genetic risk factors are the main accused that can cause inhibitor 
formation in hemophilia patients, but are less important in RBDs. In this 
review study, we searched Medline and Web of Science databases for English 
sources and the following key words: hemophilia, inhibitor, rare bleeding 
disorder, a rare inherited disorder, acquired hemophilia, acquired rare 
bleeding disorders, treatment complication, genetic in hemophilia, 
polymorphism in rare bleeding disorder, mutation in hemophilia and other 
required keywords. Hemophilia A (HA) patients who had the large deletion, 
nonsense mutation or intron 22 inversion are more susceptible to inhibitor 
development. Gene polymorphisms in the immune system are also considered 
as other risk factors in HA patients. 
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Inherited coagulation disorders are a variety of 
bleeding disorders with highly variable prevalence 
and different pattern of inheritance. These bleeding 
disorders can have a high prevalence such as 
hemophilia A (HA) with a prevalence of 1 in 5000 
male or be as rare as factor XIII deficiency (FXIIID) 
with estimated incidence of 1 in 2 million in the 
general population.  
A wide spectrum of bleeding disorders was 
observed in patients with inherited coagulation 
disorders that are more severe in patients with HA 
and hemophilia B (HB) in comparison with rare 
bleeding disorders (RBD) that including inherited 
deficiency of factors I (FI), II (FII), V (FV), combined 
V and VIII (FV-VIII), VII (FVII), X (FX) and as well 
as XI (FXI) and XIII (FXIII) (1, 2). Based on severity 
Bamedi et al.                                                                       Genetic Risk Factors for Inhibitor Development in Patients  
 Journal of Cellular & Molecular Anesthesia (JCMA) 
 
20 
of  coagulation factor deficiency, patients with 
inherited deficiency of coagulation factors need 
regular or on demand exogenous factor replacement 
therapy. 
Exposure to exogenous factors in these patients 
is a risk factor for inhibitor development. This 
inhibitor Interferes with transfused factor and 
rendering them ineffective. Rate of inhibitor 
development is vary in patients with inherited factor 
deficiencies and depend on type of deficiency 
(common or RBD) and severity of deficiency (mild, 
moderate and severe deficiency) as well as type and 
frequency of replacement therapy (3). Although 
inhibitor development is rarely observed in patients 
with deficiency of FVII and FX but is more common 
in patients with FV and FXIII deficiencies and 
consider as the most significant complication of 
treatment in hemophilia patient (4).  
Inhibitor development in patients with 
hemophilia causes high rate of morbidity such as high 
rate of bleeding diathesis, increased disability and 
decreased quality of life. Rate of inhibitor 
development is more common in patients with severe 
HA than mild and moderate deficiency and was 
observed up to 30% of severe deficient patients (5). In 
other word, overall inhibitor prevalence of 5–7% and 
when limited to patients with severe disease the 
prevalence is much higher at 12–13%. The incidence 
of new FVIII inhibitors in patients with severe FVIII 
deficiency is approximately 30%. Inhibitors are less 
common in patients with mild or moderate 
hemophilia occurring in approximately 3–13% of 
patients. 
Most of these inhibitors are high titer (>5 BU) 






Incidence Rate of inhibitor 
development 
Risk factors 
I recessive 1: 1 milion Extremely rare Replacement therapy 
II recessive 1: 2000000 Extremely rare Replacement therapy 
V recessive 1: 1 million Rare Infections, surgical procedures, transfusion and 
antibiotics administration malignancy, pregnancy 
and autoimmune diseases, exposure to topical bovin 
preparation. 
V-VIII recessive 1: 2 million Rare Replacement therapy 
VII recessive 1: 500000 Extremely rare Replacement therapy 
VIII Sex-linked 1: 10000 Up to 30% ethnicity, Family history of inhibitors, the HLA 
complex genotype, interleukin 10 and tumor 
necrosis factor α (TNF- α) polymorphisms,   factor 
VIII mutation type, age at first treatment, intensity 
of treatment, continuous infusions. 
IX Sex-linked 1 :30000 Up to 10% Replacement therapy 
X recessive 1 : 500000 Extremely rare Replacement therapy 
XI recessive 1 : 1000000 Rare Replacement therapy, using Fresh Frozen Plasma as 
a substitution, type II Jewish mutation (Glu117 
stop), antifibrinolytic agent. 
XIII recessive 1 : 1000000 Rare Using durgs, cohns disease, liver disease,  
leukemia, disseminated intravascular coagulation, 
ulcerative colitis, Henoch Schonlein  Purpura, 
inflammatory bowel disease, sepsis, stroke, 
pulmonary embolism, systematic lupus 
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and were developed shortly after exposure to 
exogenous FVIII. Factor VIII  consists of two chains 
including a heavy chain with A1 and A2 domains, a 
connecting region with a B1 domain that is not 
required for clotting, and a light chain with A3, C1, 
and C2 domains (Figure 1). Most of the inhibitors 
are directed against C2 domain and less often A2 
domain. C2 doamin binds to von Willebrand factor, 
phosphatidylserine on activated platelets and and 
inhibitor against this domain causes decrease 
procoagulant activity of FVIII. Specific mutation 
such as Trp2229Cys  in C2 domain and Arg593Cys  
in A2 domain may predispose  to inhibitor formation 
(3-5). 
Rate of inhibitor development is less in patients 
with HB and can be observed in about 3-5% of these 
patients. As previously mentionedoOne of the most 
important risk factor, is underlying gene defects and 
since missemse mutations as the main cause of HB 
are consider as low risk factor for inhibitor 
development, inhibitor is less common in HB.  The 
rate of inhibitor development affected by different 
factors and genetic risk factors consider as an 
important factor in this issue (6). Genotype of patients 
with HA is an important factor in formation of 
inhibitor. It was demonstrated that patients with large 
deletion, nonsense mutation and intron 22 inversion 
has a higher risk of inhibitor formation. Some 
missense mutation even in patients with mild and 
moderate deficiency increased the risk of inhibitor 
formation.  
Gene polymorphisms are other genetic risk 
factor for inhibitor development in patients with 
hemophilia and a consider number of studies were 
conducted on role of interleukins and tumor necrosis 
factor α (TNF-α) on inhibitor development in 
different populations. A number of these studies were 
demonstrated a role for genetic polymorphisms in IL- 
10 and TNF-α in inhibitor development in patients 
with HA (7-9). Gene polymorphisms in coagulation 
FII and FV leiden also were performed and some 
important result were obtained and polymorphisms of 
these factors consider as another culprit but more 
studies with large population and prospective nature 
should performed to demonstrated this issue. In 
contrast to haemophilia A, in others inherited 
coagulation factor deficiencies due to the rarity of 
disorders and absent of common mutations and 
polymorphisms in some of them, there is no clear 
relation found between genetic risk factors and 
development of an inhibitors. 
Developing inhibitors against factor V is rarely 
occur but it’s a challenging condition that can be 
potentially lifethreatening. Factor V inhibitors can 
develop without any clear causes but most of cases 
associated with clinical events including infections, 
surgical procedures, transfusion and antibiotics 
administration. In addition, malignancy, pregnancy 
and autoimmune diseases can also lead to developing 
inhibitors (10).  
In the past, coagulation factor V inhibitors 
more frequently resulted from patient’s exposure to 
topical bovine preparations but today due to the 
availability of recombinant bovine and also 
recombinant human thrombin, surgical use of 
thrombin is restricted (11, 12). Therefore most cases 
associated with non bovine thrombin preparations. 
Bovine thrombin is mixed with fibrinogen to form 
sealant that used in surgical procedures (cardiac 
surgery and neurosurgery) to aid homeostasis. 
Because the thrombin contains bovine factor V its act 
as a potent stimulus for development of antibodies. 
Clinical manifestations of patients affected by factor 
V inhibitors vary from asymptomatic to 
lifethreatening episodes. Some studies showed the 
relation between plasma residual factor activity and 
bleeding tendencies among patients with acquire 
factor V deficiency (13). In patients with severe factor 
XI deficiency as other rare bleeding disorders, 
developing inhibitors against factor XI had been 
described. Almost in all cases that develop inhibitors , 
patients had received replacement therapy (14) .in the 
 
Fig. 1.  Coagulation factor VIII structure. Factor VIII consists of a heavy chain with A1 and A2 domains, a 
connecting region with a B1 domain that is not required for clotting, and a light chain with A3, C1, and C2 
domains. Most of inhibitor against factor VIII, bind to the C2 or, less often, the A2 domain on factor VIII (1) 
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study that conducted on 118 patients with factor XI 
deficiency, seven patient that received fresh frozen 
plasma as a substitution therapy developed an 
inhibitors that titers from 3 to 25 BU/ml.  Molecular 
analysis was demonstrated that all of these patients 
were homozygote for so-called type II Jewish 
mutation (Glu117stop).  
This study suggested only patients with 
homozygote or compound heterozygote develop 
inhibitors. In some situations, using antifibrinolytic 
agents lead to reasonable response. In addition based 
on different studies in cases those are not responsive 
to antifibrinolytic agents, use of rVIIa is 
recommended (15).  
Although factor XIII inhibitors are also arise 
very rarely but same as acquired factor V deficiency 
and contrary to other rare bleeding disorders have 
more frequency. Factor XIII inhibitors arise from 
underlying disorders and in some cases result from 
using drugs (16). In acquired factor XIII deficiency 
with inhibitors bleeding episodes are lifethreatening 
and based on some studies several subjects died due 
to cerebral hemorrhage. Autoantibodies that form 
against factor XIII lead to decrease production or 
increased consumption of coagulation factor XIII 
(17).  Disease that associated with developing 
inhibitors against factor XIII including Crohn s 
disease, liver disease, leukemia, disseminated 
intravascular coagulation, ulcerative colitis, Henoch 
Schonlein Purpura, inflammatory bowel disease, 
sepsis, stroke, pulmonary embolism and systematic 
lupus erythromatosis. In addition, factor XIII 
inhibitors are associated with autoimmune diseases as 
neutralizing or non-neutralizing types. Neutralizing 
types have effect on activation of factor XIII while 
non-neutralizing form an immune complex that later 
cleared by reticuendothelial system. 
Immunosupression therapy, plasmapheresis 
and intravenous gamma globulins can be used for 
elimination of inhibitors (18). 
Conclusion 
Rate of inhibitor formation is affected by 
several factors but genetic risk factors seem to be the 
most crutial. These facrors can be used for 
identification of higher risk  patients and further for 
management of them. 
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